How Obama’s FDA keeps generic drugs off the market
(By Scott Gottlieb, MD for AEI) One of the biggest factors fueling the angst over drug prices in the U.S.
Read More
Part D/Prescription Drugs
Experimental cancer therapy holds great promise — but at great cost
(by Meghana Keshavan for STAT) Soon after she received the treatment, Karen Koehler’s brain swelled. Her blood pressure plummeted. As
Read MoreSenators press Mylan Labs over ‘outrageous’ EpiPen pricing
(By Ed Silverman for STAT) Move over, Martin Shkreli. Get in line, Valeant Pharmaceuticals. Congress appears to have found another
Read MoreMany clinical trials’ findings never get published. Here’s why that’s bad
(By Ivan Oransky and Adam Marcus for STAT) When a bearded dude at a Brooklyn coffee house says he’s shopping
Read MoreThis is your brain on pot: Neuroscientist studies long-term effects of medical marijuana
(By Leah Samuel for STAT) BELMONT, Mass. — Staci Gruber vividly remembers her first hit of marijuana, back when she
Read MoreGetting Better Data on Which Drugs Are Killing People
(By Christine Vestal for The PEW Charitable Trust) AUBURN, Ala. — As the opioid epidemic surges, Alabama’s toxicologists are testing
Read MoreDo incentives nudge physicians to prescribe opioids for pain?
(By Dhruv Khullar and Anupam Jena for STAT) Humans have used opioids to treat pain, both physical and mental, for
Read MoreIncreased Medicare Part D Spending
According to new data released by the Centers for Medicare and Medicaid Services from 2013 to 2014 spending on Medicare
Read MoreDonald Trump’s trade talk is making the drug industry uneasy
(By Dylan Scott for STAT) WASHINGTON — The drug industry is quietly troubled over Donald Trump’s tough talk on trade. Continue reading
Read MoreACLU threatens to sue Colorado over hepatitis C drug restrictions
(By Ed Silverman for STAT) In the latest dust-up over the high cost of hepatitis C drugs, the American Civil
Read More